Telomerase plays a critical role in the development of cellular immortality and oncogenesis. Activation of telomerase occurs in a majority of human malignant tumours, and the relation between telomerase and vulnerability to drug-mediated apoptosis remains unclear. In this study, we demonstrate, for the first time, up-regulation of telomerase activity in human pancreatic cancer cells treated with etoposide, a topoisomerase II inhibitor. Exposure of MIA PaCa-2 cells to etoposide at various concentrations (1-30 µM) resulted in two-to threefold increases in telomerase activity. Up-regulation was detectable 24 h after drug exposure and was accompanied by enhanced expression of mRNA of the human telomerase reverse transcriptase. Telomerase activation was also observed in AsPC-1 and PANC-1 cells but not in KP-3 and KP-1N cells. Furthermore, we found a negative correlation between increased telomerase activity and the percentage of dead cells after etoposide treatment. These findings suggest the existence of an anti-apoptotic pathway through which telomerase is up-regulated in response to DNA damage. This telomerase activation pathway may be one of the mechanisms responsible for the development of etoposide resistance in certain pancreatic cancer cells.
Despite tremendous efforts in early diagnosis and therapy, the prognosis for patients with pancreatic carcinoma remains dismal (Warshaw and Fernandez-del Castillo, 1992; Niederhuber et al, 1995) . In advanced pancreatic cancer, drug resistance is a major obstacle to chemotherapy (Arbuck, 1990; Lionetto et al, 1995; Schnall and Macdonald, 1996) . Considerable evidence shows that apoptosis plays a key role in tumour cell death induced by several chemotherapeutic agents (Kerr et al, 1994; Huschtscha et al, 1996) . Tumour cells may express defects in the apoptotic pathway and become resistant to chemotherapy (Thompson, 1995; Hickman, 1996; Reed et al, 1996) . A better understanding of the mechanisms underlying the resistance to drug-mediated apoptosis may enhance our ability to treat pancreatic cancer successfully.
Telomerase, a ribonucleoprotein enzyme, elongates and maintains telomeric DNA through the addition of TTAGGG repeats and plays a critical role in the development of cellular immortality and carcinogenesis (Morin, 1989; Harley et al, 1994; Kim et al, 1994; Shay and Bacchetti, 1997) . We previously reported highly elevated telomerase activity in 80% of specimens from surgically resected lesions of pancreatic carcinoma and in 75% of pancreatic juice samples obtained from patients with ductal carcinoma (Suehara et al, 1997a (Suehara et al, , 1997b . Three major components of human telomerase have been identified: human telomerase RNA, hTERC (Feng et al, 1995) ; telomerase-associated protein, TEP1 (Harrington et al, 1997; Nakayama et al, 1997) ; and human telomerase reverse transcriptase, hTERT (Meyerson et al, 1997; Nakamura et al, 1997) . Among these components, hTERT has been considered a catalytic subunit of telomerase and a ratelimiting determinant of the enzymatic activity (Bodnar et al, 1998; Vaziri and Benchimol, 1998) .
Although telomerase may be implicated in the cellular response to apoptosis, the relation between telomerase and vulnerability to apoptosis remains poorly understood. Antisense inhibition of telomerase increases the susceptibility of glioblastoma cells to cisplatin-induced apoptosis (Kondo et al, 1998) . Similarly, telomerase inhibition with the oligodeoxynucleotide enhances apoptosis in pheochromocytoma cells induced by a variety of stimuli (Fu et al, 1999) . Enhanced expression of telomerase and maintenance of telomere stability increase cellular resistance to apoptosis triggered by serum starvation or matrix deprivation (Holt et al, 1999) . These findings suggest a protective role of telomerase against apoptotic cell death. We hypothesized that telomerase activity could be one determinant of vulnerability to drug-induced apoptosis. Studies on telomerase regulation in cancer cells treated with antineoplastic agents could elucidate the functional role of this enzyme in drug-induced apoptosis.
In the present study, we investigated the dynamics of telomerase activity in human pancreatic cancer cells treated with etoposide, which is known to cause DNA strand breaks and to induce apoptosis in diverse cell types (Barry et al, 1993; Mizumoto et al, 1994; Okamoto-Kubo et al, 1994; Bonelli et al, 1996; Lock and Stribinskiene, 1996; Hande, 1998) . We found increased telomerase activity after etoposide exposure in cell lines that showed resistance to etoposide-induced apoptosis. To the best of our knowledge, this is the first report describing up-regulation of telomerase activity in response to etoposide. Our results support the hypothesis that telomerase plays a protective role against DNA damage and subsequent apoptosis through its up-regulation pathway.
MATERIALS AND METHODS

Cell lines and culture conditions
Five human pancreatic cancer cell lines were used in this study: MIA PaCa-2 was provided by the Japanese Cancer Resource Bank (Tokyo, Japan); AsPC-1, PANC-1, KP-3, and KP-1N were donated by Dr Iguchi (National Kyushu Cancer Center, Fukuoka, Japan). Cells were maintained in Dulbecco's modified Eagle's medium (Sigma Chemical Co., St Louis, MO, USA) supplemented with 10% fetal bovine serum, streptomycin (100 µg ml -1 ), and penicillin (100 U ml -1 ) at 37°C in a humidified atmosphere containing 10% carbon dioxide.
Drug treatment
Etoposide (Nippon Kayaku Co., Ltd., Tokyo, Japan) was dissolved in dimethylsulphoxide (DMSO) at 10 mM as a stock solution. Cells in log phase growth were seeded at a density of 5 × 10 4 cells well -1 in 12-or 24-well plates. After overnight incubation, the cells were exposed continuously to etoposide at various concentrations. Cell number and mean cell diameter were measured with a particle distribution analyser, CDA500 (Sysmex, Kobe, Japan). Five days after the beginning of treatment, cell viability was assessed with the cell-death assay described below. 
Measurement of DNA synthesis
Cell cycle analysis
Cells were harvested at indicated time points, washed twice in phosphate-buffered saline (PBS) and fixed with cold 70% ethanol for 4 h at 4°C. Fixed cells were then washed with PBS, incubated with RNAase (100 µg ml -1 ) for 30 min at room temperature, stained with propidium iodide (PI, Sigma, 50 µg ml -1 ) and analysed on a FACScan flow cytometer (Becton Dickinson, Bedford, MA, USA).
Assessment of apoptosis
After drug treatment, detached cells were combined with monolayer cells that had been detached by trypsinization and applied to glass slides with cytospin preparations. Cells were fixed in cold methanol, and membranes were permeabilized with 0.2% Triton X-100 (Sigma) and stained with DNA dye, PI. Nuclear morphology was observed under a laser-scanning microscope, Olympus LSM-GB200 system (Tokyo, Japan).
Quantitative measurement of dead cells
Dead cells were measured quantitatively with a multiwell fluorescence scanner by the method described previously (Sato et al, 1998 ). This method is based on the binding of PI to the nuclei of cells with plasma membranes that are permeable as a result of cell death. The percentage of dead cells was defined as the proportion of fluorescence intensity corresponding to dead cells to that of total cells.
Telomerase activity assay
Telomerase activity was measured based on a telomerase repeat amplification protocol (TRAP) assay performed with a TRAPeze Telomerase Detection Kit (Intergen, Purchase, NY, USA) according to the manufacturer's instructions. For a sensitive and semiquantitative telomerase assay, cell extracts were diluted to a concentration equivalent to a constant number of cells for each assay. PCR products were resolved by electrophoresis on a 12% polyacrylamide gel and visualized with SYBR Green DNA stain (FMC Bioproducts, Rockland, ME, USA). A 36-bp internal standard was used as an internal control. For quantification of telomerase activity in each sample, the total density of the entire ladder was measured with NIH-Image software (NTIS, Springfield, VA, USA).
RT-PCR analysis
Analysis of the mRNA expression of hTERT, TEP1 and hTERC was performed by reverse transcription polymerase chain reaction (RT-PCR) amplification. An Isogen RNA extraction kit (Nippon Gene, Tokyo, Japan) was used to isolate total RNA from the cell pellets. cDNA was synthesized from 2 µg of RNA with the RNA PCR kit (Takara Shuzo Co. Ltd, Otsu, Japan) and random primers. Two-microlitre aliquots of the reverse-transcribed cDNA were subjected to PCR amplification with an initial incubation step at 94°C for 3 min, followed by 33 cycles at 94°C for 45 s, 60°C for 45 s and 72°C for 90 s. The primer pairs were as follows: 5′-TGAGTGTGTACGTCGTCGAG-3′ (sense) and 5′-GAACG-TTCTGGCTCCCACGA-3′ (antisense) for hTERT; 5′-TCA-AGCCAAACCTGAATCTGAG-3′ (sense) and 5′-CCCCGAGT-GAATCTTTCTACGC-3′ (antisense) for TEP1; and 5′-TCTAAC-CCTAACTGAGAAGGGCGTAG-3′ (sense) and 5′-GTTTGCT-CTAGAATCAACGGTGGAAG-3′ (antisense) for hTERC. The PCR products were separated on a 2% agarose gel and visualized by ethidium bromide staining.
Statistical analysis
The results of parametric data are expressed as means ± standard deviation (s.d.) . Correlation between the magnitude of telomerase up-regulation and the percentage of dead cells was assessed with the Spearman's rank correlation test. P < 0.05 was considered significant.
RESULTS
Cytotoxic effect of etoposide on MIA PaCa-2 cells
We first evaluated the cytotoxicity of etoposide on MIA PaCa-2 cells. Control cells were treated with solvent (DMSO) alone. Treatment with etoposide (5 µM) completely inhibited the growth of MIA PaCa-2 cells ( Figure 1A ). DNA synthesis, determined by the [ 3 H]thymidine incorporation test, decreased after etoposide exposure. The [ 3 H]thymidine uptake in cells treated with 5 µM etoposide for 24 h was 41.8 ± 0.3% that of control cells. Flow cytometric analysis revealed that the cells were arrested at the G2/M phase 48 h after etoposide treatment. In control cells, the phase values were 50% for G0/G1, 39% for S, and 11% for G2/M. In cells treated with etoposide for 48 h, the values were 21% for G0/G1, 22% for S, and 57% for G2/M. Morphologically, cells exposed to etoposide were enlarged with a mean cell diameter of 24.7 ± 3.7 µm 24 h after treatment compared to 21.3 ± 3.0 µm in control cells ( Figure 1B) . Apoptotic cell death, characterized by cell shrinkage, plasma membrane blebbing, chromatin condensation and nuclear fragmentation, was detectable in a small number of cells beginning on day 3 ( Figure 1C ). The percentage of dead cells in the culture treated with 5 µM etoposide was 7.7 ± 1.2% on day 5. Almost no cell death was observed in solvent-treated cells (data not shown).
Up-regulation of telomerase activity in MIA PaCa-2 cells treated with etoposide
To determine an appropriate concentration (cell number equivalent) of cell extract that would permit reliable quantification of relative levels of telomerase activity, the basal level of telomerase activity was measured in a serial dilution of the MIA PaCa-2 cell extract. One hundred to 3000 cell equivalents were within linear range of the relative telomerase activity (Figure 2A ). In subsequent assays, we applied extracts equivalent to 10 2 cells to precisely detect differences in telomerase activity. Twenty-four hours after treatment with etoposide at various (0.1-30 µM) concentrations, we examined MIA PaCa-2 cells for changes in telomerase activity. Etoposide significantly enhanced telomerase activity of treated cells even at relatively low doses ( Figure 2B Figure 2C ). After 72 h, telomerase activity decreased gradually and returned to the pretreatment level at 96 h. When etoposide was added directly to MIA PaCa-2 cell extracts immediately before primer addition, telomerase activity remained unchanged (data not shown). Thus, a direct influence of etoposide on TRAP assay does not seem to be involved in the telomerase activation observed after drug treatment.
Effect of etoposide on mRNA expression of hTERT, TEP1 and hTERC in MIA PaCa-2 cells
We also examined the effect of etoposide on the mRNA expressions of three telomerase subunits, hTERT, TEP1 and hTERC by RT-PCR. MIA PaCa-2 cells treated with etoposide (5 µM) displayed a substantial increase in hTERT mRNA expression (Figure 3 ). The increased level was detectable at 24 h, peaked at 48 h after drug exposure, and paralleled the up-regulation of telomerase activity encountered in the treated cells. In contrast, no significant increase was observed in TEP1 and hTERC mRNA levels during etoposide treatment. These results suggest that hTERT plays a critical role in the regulation of telomerase activity and that etoposide up-regulates telomerase activity of treated cells through induction of hTERT mRNA expression.
Relation between telomerase up-regulation and sensitivity to etoposide-induced cell death
Other cell lines were treated with etoposide at a concentration of 5 µM and assayed for telomerase activity in the same manner. AsPC-1 and PANC-1 cells exhibited an increase in telomerase activity, whereas KP-3 and KP-1N cells showed no significant change after etoposide treatment ( Figure 4 and Table 1 ). Since telomerase is implicated in the anti-apoptotic phenotypes, we attempted to determine whether a correlation exists between telomerase activity and etoposide-induced apoptosis. MIA PaCa-2, AsPC-1 and PANC-1, all of which showed telomerase elevation, were relatively resistant to etoposide-mediated apoptosis. The percentage of dead cells at day 5 was 7.7 ± 1.2% in MIA PaCa-2, 2.5 ± 0.8% in AsPC-1, and 21.8 ± 2.7% in PANC-1 (Table 1) . KP-3 and KP-1N, with unchanged telomerase activity, were sensitive to etoposide-induced lethality. The proportion of dead cells was 37.5 ± 5.4% in KP-3 and 54.5 ± 0.8% in KP-1N. The magnitudes of telomerase up-regulation (the ratio of the highest telomerase activity to that of control cells) in these five lines were significantly correlated with the percentages of dead cells (P < 0.05; Figure 5 ). These findings indicate that some types of pancreatic cancer cells may escape etoposide-induced apoptotic crisis via the mechanism of telomerase activation.
DISCUSSION
The aim of this study was to investigate the effect of etoposide on telomerase activity and to clarify the relation between telomerase dynamics and etoposide-mediated apoptotic cell death. The results demonstrate that etoposide enhances telomerase activity in human pancreatic cancer cells by including its catalytic subunit hTERT mRNA expression. Our findings have implications for understanding the potential role of telomerase in cancer cells.
Our present data conflict with previous studies that found no significant change in telomerase activity in leukaemic cells and nasopharyngeal carcinoma cells after etoposide treatment (Ku et al, 1997; Akiyama et al, 1999) . Direct comparison of these studies and ours is difficult because of differences in cell lines used and in methodologies. Telomerase plays an essential role in the maintenance of genomic integrity (Lee et al, 1998) , and its activation upon exposure to etoposide could result from the need of cells to repair DNA. This idea is supported by a study describing the stabilization of broken chromosomes by the direct addition of telomeric repeats to nontelomeric DNA (Flint et al, 1994) . Healing process of broken DNA might be mediated by telomerase. Consistent with our present results, a previous report showed up-regulation of telomerase activity in haematopoietic cells after exposure to ionizing radiation (Leteurtre et al, 1997) .
Factors suggested to influence telomerase activity include cellular proliferation, cell cycle progression, differentiation, cellular senescence and apoptosis. Telomerase activity is associated with cell proliferation (Belair et al, 1997) . However, our data show that etoposide inhibits the growth and DNA synthesis of treated cells rather than promotes their proliferation. The relation between telomerase activity and cell cycle is controversial (Holt et al, 1997) . During cell cycle progression, telomerase activity has been noted as highly activated in the S phase and barely detectable in the G2/M phase (Zhu et al, 1996) . We found that etoposide arrested most cells at the G2/M phase of the cell cycle by 48 h after treatment, when the telomerase up-regulation was maximal. Telomerase elevation in response to etoposide may not be related to the cell cycle-dependent modulation of this enzyme. Telomerase activity is also modulated by apoptosis. When tumour cell lines were treated with antineoplastic agents, including cisplatin and adriamycin, drug-induced cell killing was associated with a decline in telomerase activity (Faraoni et al, 1997) . Apoptotic cells with an intact plasma membrane were reported to maintain high telomerase activity, whereas cells with plasma membrane damage lost telomerase activity (Akiyama et al, 1999) . In our present study, telomerase elevation was detectable as early as 24 h after etoposide exposure, prior to the appearance of apoptotic cell death. After 72 h, telomerase activity slowly decreased, which is consistent with the loss of enzymatic activity resulting from apoptotic cell death. Etoposide-mediated telomerase activation may be a relatively early event that is independent of cell proliferation, cell cycle and apoptotic cell death.
We also examined the linkage between telomerase activity and vulnerability to etoposide-induced apoptosis. Although some investigators have suggested an anti-apoptotic role of telomerase in different cell types, the functional role of this enzyme in the drug-induced apoptosis remains poorly understood. We did not observe a significant relation between the basal level of telomerase activity in individual lines and their susceptibilities to etoposideinduced apoptosis (results not shown). We did find a negative correlation between increased telomerase activity and the percentage of dead cells after etoposide treatment. These findings raise the possibility that the elevated activity of telomerase can confer a survival advantage upon tumour cells and contribute to their decreased sensitivity to etoposide-mediated apoptosis. Detection of telomerase elevation, rather than the basal level of the enzyme, could be efficacious in determining the potential success of chemotherapy.
Susceptibility to drug-induced apoptosis is modulated by various genetic and biochemical alterations. For example, p53 tumour suppressor gene product is essential for proper induction of apoptosis (Lowe et al, 1993 (Lowe et al, , 1994 . Tumour cells harbouring mutant p53 are generally more resistant to DNA damaging agents, such as etoposide, than cell expressing wild-type p53 (Fan et al, 1994; Perego et al, 1996; O'Connor et al, 1997) . Regarding the p53 gene status, all the lines used in this study have p53 mutations except for KP-3 (Iguchi et al, 1994) . Thus, p53 alone can not explain the different responses to etoposide-induced cell killing between these cell lines. Several complex factors, such as other genes controlling apoptosis, may be involved in the mechanisms underlying drug resistance of cancer cells. Our present results suggest that telomerase activation might be one of the key events responsible for the development of drug resistance in certain tumour cell types.
In conclusion, we observed increased telomerase activity after etoposide exposure. Although further studies will be required to delineate the precise mechanism by which telomerase activity is Relation between the magnitude of telomerase up-regulation and vulnerability to etoposide-induced apoptosis in five pancreatic cancer cell lines. There is a significant negative correlation between maximum telomerase activity (ratio to control) upon exposure to etoposide and percentage of dead cells at day 5 (P < 0.05) up-regulated in response to DNA damage, our data suggest that a close linkage exists between vulnerability to drug-mediated apoptosis and activation of telomerase in human pancreatic cancer cells. A targeted blockage of this telomerase elevation pathway could be a potential anticancer strategy for sensitizing tumour cells to certain antineoplastic agents.
